at Investor's Business Daily (Mon, 6:42PM)
Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan...
Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan with a price target of $32 a share. Analyst Brian Abrahams thinks the competitive threats to VPHM's Angioedema treatment Cinryze have been overstated relative to its peers, noting that although some early-stage treatments by its competitors are "worth keeping an eye on," they have characteristics which make them a less-attractive alternative.
From other sites
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at Zacks.com (Jan 15, 2015)
at Benzinga.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs